Last 47 quarters of trend data · Healthcare · Medical - Instruments & Supplies
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Sanara MedTech Inc.'s quarterly P/E stands at 11.7x. EV/EBITDA has compressed 76.3% YoY to 14.4x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -4.38 | 11.68 | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 1.65 | 1.83 | 2.69 | 2.37 | 2.82 | 2.69 | 2.97 | 2.96 | 4.20 | 4.96 | 4.05 | 5.24 | 5.43 |
| — | -32.0% | -9.4% | -20.2% | -32.8% | -45.7% | -26.6% | -43.4% | -22.6% | -19.6% | -12.3% | +18.9% | -21.7% | |
| P/B Ratio | 27.75 | 33.96 | 46.26 | 6.91 | 7.22 | 7.28 | 6.53 | 5.77 | 7.24 | 7.87 | 5.88 | 8.05 | 8.13 |
| — | +366.5% | +608.7% | +19.7% | -0.4% | -7.5% | +11.0% | -28.3% | -10.9% | -13.1% | +9.1% | +67.6% | +7.0% | |
| P/FCF | 78.85 | 13.03 | 63.50 | 67.72 | — | 84.66 | 31.54 | — | — | — | 72.55 | — | — |
| — | -84.6% | +101.3% | — | — | — | -56.5% | — | — | — | — | — | — | |
| EV / EBITDA | 20.27 | 14.39 | 22.25 | 63.03 | — | 60.73 | — | — | — | 102.86 | 727.89 | — | — |
| — | -76.3% | — | — | — | -41.0% | — | — | — | — | — | — | — | |
| EV / EBIT | 27.66 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Sanara MedTech Inc.'s operating margin was 15.4% in Q4 2025, up 4.2 pp QoQ and up 16.8 pp YoY. This marks the 4th consecutive quarter of margin expansion, signaling a sustained improvement in operating efficiency. The trailing four-quarter average of 4.4% lags the current quarter, suggesting the recent improvement is above-trend.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 92.7% | 93.2% | 92.9% | 92.5% | 92.2% | 91.4% | 90.8% | 90.0% | 89.8% | 89.9% | 89.1% | 86.1% | 86.3% |
| — | +1.9% | +2.3% | +2.7% | +2.6% | +1.7% | +2.0% | +4.6% | +4.1% | +6.3% | +7.4% | -4.4% | -3.8% | |
| Operating Margin | 7.1% | 15.4% | 11.2% | -0.1% | -8.9% | -1.4% | -8.9% | -14.3% | -8.3% | -1.3% | -5.7% | -11.8% | -7.8% |
| — | +1180.1% | +225.8% | +99.2% | -7.4% | -11.6% | -56.9% | -20.8% | -5.4% | +93.7% | +77.2% | +66.2% | +78.0% | |
| Net Margin | -36.4% | -5.9% | -115.5% | -7.8% | -15.1% | -5.8% | -13.2% | -17.4% | -9.5% | -1.3% | -6.6% | -11.6% | -7.6% |
| — | -0.0% | -775.8% | +55.1% | -58.1% | -336.2% | -99.3% | -49.8% | -25.4% | +95.0% | +41.3% | -245.8% | +81.1% |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -167.5% | -26.7% | -146.5% | -5.6% | -9.3% | -3.9% | -7.1% | -8.3% | -4.0% | -0.5% | -2.5% | -4.4% | -2.8% |
| — | -579.8% | -1972.1% | +32.7% | -131.7% | -634.1% | -183.5% | -87.2% | -42.2% | +94.4% | +32.1% | -284.3% | +73.5% | |
| ROA | -58.9% | -2.9% | -35.8% | -2.1% | -3.8% | -1.7% | -3.5% | -4.9% | -2.4% | -0.3% | -1.6% | -3.1% | -1.9% |
| — | -67.3% | -914.5% | +57.5% | -56.9% | -448.5% | -122.6% | -57.1% | -25.2% | +95.3% | +41.8% | -261.5% | +78.1% | |
| ROIC | 11.8% | 8.3% | 4.3% | -0.0% | -2.7% | -0.5% | -2.7% | -4.2% | -2.2% | -0.3% | -1.6% | -3.8% | -2.6% |
| — | +1738.8% | +259.1% | +99.1% | -20.7% | -51.7% | -72.5% | -9.5% | +14.7% | +95.1% | +81.1% | +73.0% | +84.5% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Sanara MedTech Inc.'s Debt/EBITDA ratio is 11.9x, down from 13.3x last quarter — elevated, raising questions about debt serviceability. The current ratio has weakened 17.3% YoY to 1.80x, tightening the short-term liquidity position. Debt/Equity has risen for 9 consecutive quarters, indicating increasing financial leverage that investors should watch closely.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 8.13 | 8.13 | 7.73 | 1.28 | 1.22 | 0.83 | 0.81 | 0.39 | 0.27 | 0.26 | 0.27 | 0.05 | 0.05 |
| — | +879.5% | +855.2% | +226.6% | +348.4% | +213.7% | +200.9% | +684.5% | +434.1% | +1246.9% | +1285.2% | +476.2% | +295.4% | |
| Debt / EBITDA | 4.84 | 11.90 | 13.34 | 41.97 | — | 26.17 | — | — | — | 13.57 | 130.29 | — | — |
| — | -54.5% | — | — | — | +92.8% | — | — | — | — | — | — | — | |
| Current Ratio | 1.80 | 1.80 | 1.80 | 2.26 | 2.77 | 2.18 | 2.23 | 1.80 | 1.35 | 1.38 | 1.46 | 1.84 | 1.79 |
| — | -17.3% | -19.2% | +25.8% | +105.7% | +57.8% | +51.9% | -2.2% | -24.8% | -14.3% | -34.5% | -35.7% | -58.3% | |
| Quick Ratio | 1.59 | 1.59 | 1.60 | 2.03 | 2.54 | 2.00 | 2.02 | 1.49 | 1.02 | 1.04 | 1.09 | 1.39 | 1.47 |
| — | -20.5% | -20.4% | +36.0% | +149.5% | +92.5% | +85.7% | +7.1% | -30.8% | -22.1% | -40.7% | -44.9% | -62.2% | |
| Interest Coverage | — | — | 1.62 | -0.02 | -1.58 | -0.29 | -2.07 | -4.48 | -5.73 | -0.79 | -4.82 | — | -202720.50 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying SMTI stock.
Sanara MedTech Inc.'s current P/E is -4.4x. The average P/E over the last 1 quarters is 11.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Sanara MedTech Inc.'s current operating margin is 7.1%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Sanara MedTech Inc.'s business trajectory between earnings reports.